Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph not_applicable
1
50%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Other(1)

Detailed Status

Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

not_yet_recruiting150%
unknown150%

Recent Activity

0 active trials
Showing 2 of 2
not_yet_recruiting

The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study

NCT07180459
unknownnot_applicable

A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC)

NCT06023147

Clinical Trials (2)

Showing 2 of 2 trials
NCT07180459

The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study

Not Yet Recruiting
NCT06023147Not Applicable

A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC)

Unknown

All 2 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
2